Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 4:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Oesophagitis, Eosinophilic Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

Comparing Anesthetic Techniques in Children Having Esophagogastroduodenoscopies

NCT02038894
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Intubated with Sevoflurane (IS), Intubated with Propofol (IP), Zofran - no intubation, Propofol
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Year to 12 Years
Enrollment
179 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 23, 2020 · Synced Jul 23, 2026, 4:33 AM EDT
Completed Not applicable Interventional

A Study of Baked Milk Tolerance to Treat Eosinophilic Esophagtis

NCT05606705
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Baked Milk
Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Jul 23, 2026, 4:33 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)

NCT04322604
View directory record Official record
Conditions
Eosinophilic Gastritis, Eosinophilic Duodenitis
Interventions
lirentelimab (AK002), Placebo
Drug · Other
Lead sponsor
Allakos Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
60
States / cities
Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2024 · Synced Jul 23, 2026, 4:33 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety APT-1011 in Adolescent Subjects With Eosinophilic Esophagitis (EoE) - A Sub-Study of the FLUTE-2 Trial

NCT05083312
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
APT-1011, Placebo oral tablet
Drug
Lead sponsor
Ellodi Pharmaceuticals, LP
Industry
Eligibility
12 Years to 17 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Indianapolis, Indiana • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Jul 23, 2026, 4:33 AM EDT
Completed No phase listed Observational

Exhaled Nitric Oxide as a Biomarker of Disease Activity in Eosinophilic Esophagitis

NCT01170234
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
NIOX MINO® Airway Inflammation Monitor
Device
Lead sponsor
Tufts Medical Center
Other
Eligibility
7 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 15, 2019 · Synced Jul 23, 2026, 4:33 AM EDT
Completed Phase 3 Interventional Results available

Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis

NCT04991935
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
CC-93538
Drug
Lead sponsor
Celgene
Industry
Eligibility
12 Years to 75 Years
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
81
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Jul 23, 2026, 4:33 AM EDT
Terminated Phase 2 Interventional Results available

Eosinophilic Esophagitis Clinical Therapy Comparison Trial

NCT01821898
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Oral Budesonide, Elimination diet
Drug · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
3 Years to 17 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 10, 2021 · Synced Jul 23, 2026, 4:33 AM EDT
Completed Phase 3 Interventional Results available

A Study in Adolescents and Adults With Eosinophilic Esophagitis (EoE) Measuring Histologic Response and Determine if Reduction in Dysphagia is Achieved

NCT02605837
View directory record Official record
Conditions
Eosinophilic Esophagitis (EoE)
Interventions
Oral Budesonide Suspension (OBS), Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
11 Years to 55 Years
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
77
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Jul 23, 2026, 4:33 AM EDT
Completed Not applicable Interventional Results available

Fluticasone Versus Esomeprazole to Treat Eosinophilic Esophagitis

NCT00895817
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Swallowed fluticasone, Esomeprazole
Drug
Lead sponsor
Walter Reed Army Medical Center
Federal
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 11, 2013 · Synced Jul 23, 2026, 4:33 AM EDT
Terminated Phase 2 Interventional Results available

Bethanechol for Eosinophilic Esophagitis

NCT02058537
View directory record Official record
Conditions
Eosinophilic Esophagitis (EoE)
Interventions
Bethanechol
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 75 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 21, 2016 · Synced Jul 23, 2026, 4:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Comparison of Esophageal Clearance Times of Oral Budesonide Preparations

NCT02125851
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Xanthan Gum, Honey
Other
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 28, 2014 · Synced Jul 23, 2026, 4:33 AM EDT
Not yet recruiting Phase 2 Interventional

A Trial of Upadacitinib for Non-responsive Eosinophilic Esophagitis

NCT07588568
View directory record Official record
Conditions
EoE, Eosinophilic Esophagitis, Eosinophilic Esophagitis (EoE)
Interventions
Upadacitinib 30mg Dose, Upadacitinib Matching Placebo
Drug · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Jul 23, 2026, 4:33 AM EDT
Completed Phase 1Phase 2 Interventional

Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome

NCT00266565
View directory record Official record
Conditions
Hypereosinophilic Syndromes, Eosinophilic Gastroenteritis, Churg-Strauss Syndrome, Eosinophilic Esophagitis
Interventions
Mepolizumab
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 28, 2020 · Synced Jul 23, 2026, 4:33 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Natural History and Genetics of Food Allergy and Related Conditions

NCT02504853
View directory record Official record
Conditions
Food Allergy, Loeys-Dietz Syndrome, Atopic Dermatitis, Eosinophilic Esophagitis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 99 Years
Enrollment
1,800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Jul 23, 2026, 4:33 AM EDT
Completed Not applicable Interventional Results available

Use of Esophageal String Test to Understand Symptoms, Inflammation, and Function in Eosinophilic Esophagitis

NCT03305653
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Esophageal String Test (EST)
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
7 Years to 17 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 5, 2021 · Synced Jul 23, 2026, 4:33 AM EDT
Completed Phase 3 Interventional

24-Week Induction Study of APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE 3)

NCT05634746
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
APT-1011, Placebo oral tablet, Esophagogastroduodenoscopy
Drug · Procedure
Lead sponsor
Ellodi Pharmaceuticals, LP
Industry
Eligibility
18 Years and older
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
59
States / cities
Dothan, Alabama • Mobile, Alabama • Scottsdale, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Jul 23, 2026, 4:33 AM EDT
Completed No phase listed Observational

Nasal Nitric Oxide Levels in Eosinophilic Esophagitis (EoE)

NCT01929824
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Oral Nitric Oxide testing
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 29, 2019 · Synced Jul 23, 2026, 4:33 AM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Esophagitis

NCT04322708
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Placebo, lirentelimab (AK002)
Other · Drug
Lead sponsor
Allakos Inc.
Industry
Eligibility
12 Years to 80 Years
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
73
States / cities
Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2024 · Synced Jul 23, 2026, 4:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study of Detergents in the Pathogenesis of Eosinophilic Esophagitis

NCT05482256
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Esophageal String Test (EST), Colgate, High Resolution Esophageal Manometry (HREM)
Diagnostic Test · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Jul 23, 2026, 4:33 AM EDT
Completed Phase 2Phase 3 Interventional Results available

The Role Of Gastroesophageal Reflux Disease (GERD) in Eosinophilic Esophagitis

NCT00728481
View directory record Official record
Conditions
Eosinophilic Esophagitis, Gastroesophageal Reflux Disease, EE, GERD
Interventions
Esomeprazole, Budesonide
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 13, 2016 · Synced Jul 23, 2026, 4:33 AM EDT
Completed Phase 2 Interventional Results available

Study of Dupilumab in Adult Participants With Active Eosinophilic Esophagitis (EoE)

NCT02379052
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
14
States / cities
Idaho Falls, Idaho • Chicago, Illinois • Urbana, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2020 · Synced Jul 23, 2026, 4:33 AM EDT
Active, not recruiting No phase listed Observational

Prospective Database for Eosinophilic Esophagitis (EoE) of Pediatric Population

NCT05176249
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Not listed
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
1 Month to 21 Years
Enrollment
300 participants
Timeline
2011 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jul 23, 2026, 4:33 AM EDT
Completed No phase listed Observational

Proton Pump Inhibitor (PPI) Responsive Eosinophilic Esophagitis EoE: Gastroesophageal Reflux Disease (GERD) or Eosinophilic Esophagitis (EoE)?

NCT01865825
View directory record Official record
Conditions
Erosive Esophagitis
Interventions
Esophageal Barium Xray
Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Jul 23, 2026, 4:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Comparing the Availability of AQ280 in the Body After Single Oral Doses of a Capsule Formulation Versus a Tablet for Oral Suspension Formulation

NCT07093008
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
AQ280 Capsule, AQ280 Tablet for Oral Suspension, Placebo Capsule, Placebo Tablet for Oral Suspension
Drug
Lead sponsor
AQILION AB
Industry
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jul 23, 2026, 4:33 AM EDT